STXS

Stereotaxis Inc. (STXS) | Rumor.io

Stereotaxis

STXS

Attention (50-day avg)0%

Attention rank (50-day avg)#3,697

Bullish sentiment (50-day avg)64%

Price to earnings ratio-5

Market capitalization126.3M

Earnings per share-0.24

Dividend yield (TTM)—

Revenue (annual)32.4M

Net income (annual)-21.6M

Social

What share of all stock conversation is about STXS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 17

Stereotaxis, Inc. (STXS) is seeing large relative volume over the past two days, with some users initiating positions and feeling like an inflection point could be upon us as Magic production ramps.
The company's robotic magnetic navigation systems are designed to enhance the treatment of arrhythmias and coronary artery disease, and some users are seeing a potential breakout and serious momentum.
Despite some users experiencing losses, others are still holding onto the stock and believe it has a great product and future, with one user considering it a steal for a long-term hold below $2.

Generated by AI

Sentiment

Of the messages about STXS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +57.14	77.74% -6.86
Bearish	—	—	0% -57.14	22.26% +6.86

Bullish· Feb 2

$STXS has broken through key resistances, with a massive 32.62M USD volume spike and a 14.04% pump to $0.2904, setting up a moon setup toward the target $0.3482.
The company's management buyback program signals strong internal conviction, leading to a decisive move for the digital asset, with $STXS surging to $0.2882, up 13.34%.
A major balance sheet strengthening for $STXS has been cited as the catalyst for its surge, with the asset trading at $0.2925, up 14.76%, and confirming a moon setup with the next target at $0.3482.

Bearish· Aug 3

$STXS is delisting to the pink sheets tomorrow due to non-compliance, which may lead to further price decline.
The stock has experienced significant intraday downward moves, with drops of -8.88% and -10.66% in a short period of time.
The delisting and potential price drop may attract short sellers, who could further contribute to the stock's downward momentum.

Generated by AI

Topics

Of the messages about STXS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	77.89%
Earnings	—	—	0%	10.18%
Technical Analysis	—	—	0%	7.37%
Controversies	—	—	0%	1.75%
Analysts	—	—	0%	2.81%
Macro	—	—	0%	0%

Earnings· Nov 9

Stereotaxis, Inc. (STXS) reported Q3 2017 earnings with an EPS of $0.21.
The company's earnings call was available to listen to live at 10:00 AM, with an on-demand recording available after.
STXS's earnings announcement included a breakdown of the company's financial performance for the quarter.

Announcements· Apr 15

Stereotaxis, Inc. (STXS) has acquired Robocath, a French company that develops robotic technologies for interventional cardiology and neurointerventions, for a maximum consideration of $45M.
The acquisition includes a $20M upfront payment, up to $25M in earnout payments contingent on FDA clearance of Robocath's next-gen system, and a potential non-dilutive financing option through EIB loans.
The deal is expected to drive sales of Stereotaxis' EMAGIN 5F and EMAGIN 0.014 disposable products, integrate with the company's Synchrony platform, and provide faster procedures while reducing doctor X-ray exposure.

Generated by AI

Community

Of the messages about STXS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	16.67%	45.1%
Newcomers	—	—	83.33%	54.9%

Regulars· May 19

Stereotaxis has integrated its robotic electrophysiology (EP) system with Abbott's EnSiteX, marking a significant step towards improving treatment of abnormal heart rhythms.
The integration is part of a larger plan to tackle the company's challenges, as outlined by CEO David during the March call, and is expected to lead to Magic clearance in Q3/Q4.
The global collaboration between Stereotaxis and Abbott will combine leading mapping and robotic technologies, enhancing patient care, physician choice, and innovation in the field of electrophysiology.

Newcomers· Jul 17

The newcomer is initiating a position in STXS, citing the company's aligned compensation package with its success and an inflection point potentially being upon them as Magic production ramps up.
The newcomer is recommending STXS, citing a base forming, improving RSI, and a bullish MACD setup, and is now watching for a breakout that could bring serious momentum.
The newcomer believes STXS has a great product and future, and thinks anything under $2.X is a steal, advocating for a long hold despite the company raising money to make its vision a reality.

Generated by AI

University of Szeged installed Hungary’s first Robotic Magnetic Navigation system in JulyOver 70 patients with all forms of arrhythmia treated robotically to date, a record pace of use globallyRobotics enabled successful treatment of patients with multiple previously failed ablation proceduresUniversity of Szeged to celebrate leadership in technology and grand opening of Robotic Cardiology Program at upcoming scientific symposium on September 8th ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ste

27d agoYahoo Finance

Citizens lowers Stereotaxis stock price target to $3 on guidance cut

1mo agoInvesting.com

Stereotaxis, Inc. Q2 2026 Earnings Call Summary

Moby summary of Stereotaxis, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Stereotaxis Q2 Earnings Call Highlights

Stereotaxis (NYSEAMERICAN:STXS) reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints. Revenue declined from the prior-year quarter be

1mo agoYahoo Finance

Earnings call transcript: Stereotaxis posts Q2 2026 revenue miss as new products gain traction

1mo agoInvesting.com

Also Discussed

Investors talking about STXS also mention

#	Name	Attention
1	Spire Inc.SR	0%new
2	AFIB - Acutus Medical, Inc.	——
3	Edap Tms S.A.EDAP	0%0
4	XOMA CorporationXOMA	0%0
5	CTIC - CTI BioPharma Corp.	——
6	Gulf Resources, Inc.GURE	0%new
7	Electromed, Inc.ELMD	0%0
8	Rockwell Medical Inc.RMTI	0%new
9	Himax Technologies Inc. Sponsored ADRHIMX	0%0
10	Research Frontiers IncorporatedREFR	0%0

Stereotaxis Inc.

Healthcare
Medical Instruments & Supplies

Stereotaxis Inc. is a cutting-edge medical technology company that specializes in robotic systems for minimally invasive surgery. The company's primary focus is on the development and commercialization of robotic navigation technologies designed to enhance the precision, safety, and efficiency of procedures within the cardiac arrhythmia treatment sector. Stereotaxis' flagship product, the Niobe Magnetic Navigation System, enables physicians to maneuver catheters with a high degree of accuracy, using magnetic fields to decrease potential complications associated with traditional manual techniques. This technology significantly impacts the healthcare sector, particularly hospitals and medical centers specializing in interventional cardiology, by improving patient outcomes and operational workflows. Based in St. Louis, Missouri, Stereotaxis plays a significant role in advancing the field of robotic surgery, contributing to the broader medical device market's growth and innovation.

Website

Location

710 North Tucker Boulevard

Saint Louis, MO, 63101

United States

Social

What share of all stock conversation is about STXS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 17

Stereotaxis, Inc. (STXS) is seeing large relative volume over the past two days, with some users initiating positions and feeling like an inflection point could be upon us as Magic production ramps.
The company's robotic magnetic navigation systems are designed to enhance the treatment of arrhythmias and coronary artery disease, and some users are seeing a potential breakout and serious momentum.
Despite some users experiencing losses, others are still holding onto the stock and believe it has a great product and future, with one user considering it a steal for a long-term hold below $2.

Generated by AI

Sentiment

Of the messages about STXS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +57.14	77.74% -6.86
Bearish	—	—	0% -57.14	22.26% +6.86

Bullish· Feb 2

$STXS has broken through key resistances, with a massive 32.62M USD volume spike and a 14.04% pump to $0.2904, setting up a moon setup toward the target $0.3482.
The company's management buyback program signals strong internal conviction, leading to a decisive move for the digital asset, with $STXS surging to $0.2882, up 13.34%.
A major balance sheet strengthening for $STXS has been cited as the catalyst for its surge, with the asset trading at $0.2925, up 14.76%, and confirming a moon setup with the next target at $0.3482.

Bearish· Aug 3

$STXS is delisting to the pink sheets tomorrow due to non-compliance, which may lead to further price decline.
The stock has experienced significant intraday downward moves, with drops of -8.88% and -10.66% in a short period of time.
The delisting and potential price drop may attract short sellers, who could further contribute to the stock's downward momentum.

Generated by AI

Topics

Of the messages about STXS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	77.89%
Earnings	—	—	0%	10.18%
Technical Analysis	—	—	0%	7.37%
Controversies	—	—	0%	1.75%
Analysts	—	—	0%	2.81%
Macro	—	—	0%	0%

Earnings· Nov 9

Stereotaxis, Inc. (STXS) reported Q3 2017 earnings with an EPS of $0.21.
The company's earnings call was available to listen to live at 10:00 AM, with an on-demand recording available after.
STXS's earnings announcement included a breakdown of the company's financial performance for the quarter.

Announcements· Apr 15

Stereotaxis, Inc. (STXS) has acquired Robocath, a French company that develops robotic technologies for interventional cardiology and neurointerventions, for a maximum consideration of $45M.
The acquisition includes a $20M upfront payment, up to $25M in earnout payments contingent on FDA clearance of Robocath's next-gen system, and a potential non-dilutive financing option through EIB loans.
The deal is expected to drive sales of Stereotaxis' EMAGIN 5F and EMAGIN 0.014 disposable products, integrate with the company's Synchrony platform, and provide faster procedures while reducing doctor X-ray exposure.

Generated by AI

Community

Of the messages about STXS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	16.67%	45.1%
Newcomers	—	—	83.33%	54.9%

Regulars· May 19

Stereotaxis has integrated its robotic electrophysiology (EP) system with Abbott's EnSiteX, marking a significant step towards improving treatment of abnormal heart rhythms.
The integration is part of a larger plan to tackle the company's challenges, as outlined by CEO David during the March call, and is expected to lead to Magic clearance in Q3/Q4.
The global collaboration between Stereotaxis and Abbott will combine leading mapping and robotic technologies, enhancing patient care, physician choice, and innovation in the field of electrophysiology.

Newcomers· Jul 17

The newcomer is initiating a position in STXS, citing the company's aligned compensation package with its success and an inflection point potentially being upon them as Magic production ramps up.
The newcomer is recommending STXS, citing a base forming, improving RSI, and a bullish MACD setup, and is now watching for a breakout that could bring serious momentum.
The newcomer believes STXS has a great product and future, and thinks anything under $2.X is a steal, advocating for a long hold despite the company raising money to make its vision a reality.

Generated by AI

Stereotaxis

Social

Jul 17

Bullish· Feb 2

Bearish· Aug 3

Earnings· Nov 9

Announcements· Apr 15

Regulars· May 19

Newcomers· Jul 17

Stereotaxis: A Real Product Story, But The Stock Already Prices In Success (NYSE:STXS)

University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program

Citizens lowers Stereotaxis stock price target to $3 on guidance cut

Stereotaxis, Inc. Q2 2026 Earnings Call Summary

Stereotaxis Q2 Earnings Call Highlights

Earnings call transcript: Stereotaxis posts Q2 2026 revenue miss as new products gain traction

Also Discussed

Stereotaxis Inc.

Company Information

Location

Stereotaxis: A Real Product Story, But The Stock Already Prices In Success (NYSE:STXS)

University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program

Citizens lowers Stereotaxis stock price target to $3 on guidance cut

Stereotaxis, Inc. Q2 2026 Earnings Call Summary

Stereotaxis Q2 Earnings Call Highlights

Earnings call transcript: Stereotaxis posts Q2 2026 revenue miss as new products gain traction

Also Discussed

Social

Jul 17

Bullish· Feb 2

Bearish· Aug 3

Earnings· Nov 9

Announcements· Apr 15

Regulars· May 19

Newcomers· Jul 17